52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
National Institutes Of Health Begins Clinical Trial Of Hydroxychloroquine And Azithromycin To Treat Covid-19
Teva Reports Q1 Non-GAAP Earnings Per Share $0.76
Teva And Celltrion Healthcare Announce Launch Of TRUXIMA Injection
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.
Biotechnology & Drugs
5 Bazel St, P O B 3190
Sol J. Barer
Independent Chairman of the Board
President, Chief Executive Officer, Director
Eliyahu Sharon Kalif
Chief Financial Officer, Executive Vice President
Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
Executive Vice President - European Commercial
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Teva Pharmaceutical said on Monday that China has given the go-ahead to its Austedo treatment for Huntington's disease.
China has given the greenlight to Teva Pharmaceutical Industries' Austedo treatment for Huntington's disease, the company said on Monday.
Israel-based Teva Pharmaceutical Industries <TEVA.TA> beat first-quarter profit forecasts on Thursday, boosted by stronger demand for generic and over-the-counter drugs and respiratory treatments.
* REVENUES FROM NORTH AMERICA SEGMENT IN Q1 OF 2020 WERE $2,082 MILLION, AN INCREASE OF $36 MILLION
Israel-based Teva Pharmaceutical Industries reported a higher-than-expected rise in first-quarter profit on Thursday, boosted by stronger demand for generic and over-the-counter drugs and respiratory products.
* INHALATION SCIENCES SIGNS CRO CONTRACT WORTH 30.5 KEUR WITH GLOBAL PHARMACEUTICAL COMPANY
* TEVA AND CELLTRION HEALTHCARE ANNOUNCE LAUNCH OF TRUXIMA® (RITUXIMAB-ABBS) INJECTION FOR RHEUMATOID ARTHRITIS, ONLY BIOSIMILAR TO RITUXAN® (RITUXIMAB) AVAILABLE IN UNITED STATES FOR THIS INDICATION
* TEVA ANNOUNCES U.S. LAUNCH OF AUTOINJECTOR FOR AJOVY® (FREMANEZUMAB-VFRM) INJECTION Source text for Eikon: Further company coverage:
Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs.
Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that helps preserve its rights to the migraine drug Ajovy.
* TEVA PHARMACEUTICAL INDUSTRIES LTD SAYS CEO KÅRE SCHULTZ'S FY 2019 TOTAL COMPENSATION WAS $11.6 MILLION VERSUS $32.5 MILLION IN FY 2018 - SEC FILING
* TEVA AND CELLTRION HEALTHCARE ANNOUNCE U.S. AVAILABILITY OF HERZUMA® (TRASTUZUMAB-PKRB) FOR INJECTION Source text for Eikon: Further company coverage:
* TEVA ANNOUNCES FDA APPROVAL OF ARMONAIR® DIGIHALER™ (FLUTICASONE PROPIONATE) INHALATION POWDER
Israel-based Teva Pharmaceutical Industries hopes to receive approval to launch its Huntington's treatment Austedo in China this year, the company's chief executive said on Wednesday.
Teva Pharmaceutical Industries <TEVA.TA> <TEVA.N> said on Wednesday that a two-year restructuring has enabled the world's largest generic drugmaker to turn a corner, as it reported slightly better than expected fourth-quarter results.
* TEVA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS
Israel-based Teva Pharmaceutical Industries reported a slightly larger-than-expected rise in fourth-quarter profit on Wednesday and forecast 2020 earnings in line with expectations.
Teva Pharmaceutical Industries on Monday signed research agreements with two leading Israeli academic institutes, a move to boost its early-stage drug development with a focus on cancer treatments.
Teva Pharmaceutical Industries Ltd <TEVA.TA> on Thursday expressed confidence in its ability to continue paying down its huge debt burden even if it is forced to pay billions of dollars to settle thousands of U.S. opioid lawsuits.
Israel-based Teva Pharmaceutical Industries reported a larger-than-expected drop in third-quarter profit on Thursday and slightly raised its full year outlook.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.